The strong efficacy and safety data from this first-in-human study de-risk the in vivo CAR-T platform and support advancement of LB2501 and pipeline candidates (LB2503, LB2505). Monitor for next data readouts, U.S. IND filing, and potential partnership interest. The stock may re-rate on platform validation.
Price Chart
Executive Summary
Legend Biotech announced first clinical proof-of-concept data for LB2501, its in vivo CD19/CD20 dual-targeting CAR-T therapy, at EHA 2026. In a Phase 1 study of 12 patients with relapsed/refractory B-NHL, LB2501 achieved 100% ORR and 83.3% CR at the higher dose level (DL2) with no DLTs, SAEs, ICANS, or deaths. The data validates the TaVec in vivo platform and positions LB2501 as a potential first-in-class off-the-shelf CAR-T therapy.
Key Facts
- 100% objective response rate (ORR) and 83.3% complete response rate (CR) at dose level 2 (DL2) in 6 patients with R/R B-NHL
- No dose-limiting toxicities, serious adverse events, ICANS, or deaths reported across all 12 patients
- Dose-dependent in vivo CAR-T expansion observed without lymphodepletion; CAR-T cells persisted up to 116 days
- Infusion-related reactions and cytokine release syndrome were all Grade 1-2; no glucocorticoids required for CRS
- Proof-of-concept established for the TaVec in vivo CAR-T platform with polyclonal vector integration and rapid vector clearance
Financial Impact
No direct financial figures reported; early-stage clinical data with potential to unlock significant pipeline value for the in vivo platform
Risk Factors
- Early-stage data with small sample size (n=12) and short median follow-up (4 months); durability and reproducibility need confirmation
- Regulatory pathway for in vivo CAR-T is novel and uncertain; manufacturing and scaling challenges remain
- Competition from other in vivo and off-the-shelf CAR-T approaches
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004120 |
| Exhibit: exh_991.htm | 0001171843-26-004120 |
| Document: f6k_061426.htm | 0001171843-26-004120 |
| Document: 0001171843-26-004120-index-headers.html | 0001171843-26-004120 |
| Document: 0001171843-26-004120-index.html | 0001171843-26-004120 |
| Document: 0001171843-26-004120.txt | 0001171843-26-004120 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.39 (+2.98%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.39 (+14.04%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.39 (+8.34%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.39 (+15.39%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.39 (+10.04%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.39 (−6.60%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.39 (−5.81%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.39 (+5.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers